Docetaxel loaded oleic acid-coated hydroxyapatite nanoparticles enhance the docetaxel-induced apoptosis through activation of caspase-2 in androgen independent prostate cancer cells

Journal of Controlled Release

Volumn 147, Issue 2, 2010, Pages 278-288

  Luo, Yun ^a   Ling, You ^b   Guo, Wusheng ^b   Pang, Jun ^a   Liu, Weipeng ^a   Fang, Youqiang ^a   Wen, Xinqiao ^a   Wei, Kun ^b   Gao, Xin ^a  

^a THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b SOUTH CHINA UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

Apoptosis; Caspase; Docetaxel; Hydroxyapatite; Nanoparticle; Prostate cancer

Indexed keywords

APOPTOSIS; BIOLOGICAL EFFECTS; CASPASES; CELL CYCLE ANALYSIS; CRITICAL EVENTS; DOCETAXEL; DRUG CARRIER; DRUG ENCAPSULATION EFFICIENCY; DRUG RESPONSE; IN-VITRO; INDUCED APOPTOSIS; KINETIC STUDY; MITOCHONDRIAL MEMBRANE POTENTIAL; MOLECULAR MECHANISM; PHOSPHOETHANOLAMINE; PROSTATE CANCER CELLS; PROSTATE CANCERS; SMALL INTERFERING RNA (SIRNA); SUSTAINED DRUG RELEASE;

APATITE; CELL CULTURE; CELL DEATH; CELL MEMBRANES; DISEASES; ENCAPSULATION; HYDROXYAPATITE; MITOCHONDRIA; NANOPARTICLES; OLEIC ACID; POLYETHYLENE GLYCOLS; POLYETHYLENE OXIDES; RNA;

DRUG PRODUCTS;

ANDROGEN; CASPASE 2; CASPASE 3; CASPASE 6; CASPASE 7; CASPASE 8; CASPASE 9; DOCETAXEL; HYDROXYAPATITE; MACROGOL 2000; NANOPARTICLE; OLEIC ACID; SMALL INTERFERING RNA;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONTROLLED STUDY; CYTOTOXICITY; DRUG RELEASE; DRUG RESPONSE; ENCAPSULATION; ENZYME ACTIVATION; ENZYME INHIBITION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; PRIORITY JOURNAL; PROSTATE CANCER; SUSTAINED DRUG RELEASE;

ANDROGENS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CASPASE 2; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; CYSTEINE ENDOPEPTIDASES; DRUG CARRIERS; DRUG COMPOUNDING; DURAPATITE; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMANS; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; NANOPARTICLES; OLEIC ACID; PARTICLE SIZE; PROSTATIC NEOPLASMS; RNA, SMALL INTERFERING; TAXOIDS;

EID: 77957016404     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2010.07.108     Document Type: Article

References (42)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun M.J. Cancer statistics, 2009. CA Cancer J. Clin. 2009, 59(4):225-249.
2. Rumohr J.A., Chang S.S. Current chemotherapeutic approaches for androgen-independent prostate cancer. Curr. Opin. Investig. Drugs 2006, 7(6):529-533.
3. Lavelle F., Gueritte-Voegelein F., Guenard D. Taxotere: from yew's needles to clinical practice. Bull. Cancer 1993, 80(4):326-338.
4. Piccart M.J. Taxanes: an action mechanism at the cellular level, significant clinical progress in the treatment of cancers of the ovary and breast. Bull. Mem. Acad. R. Med. Belg. 1998, 153(5-6):285-292. discussion 292-294.
5. Tannock I.F., de Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N., Oudard S., Theodore C., James N.D., Turesson I., Rosenthal M.A., Eisenberger M.A. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 2004, 351(15):1502-1512.
6. Picus J., Schultz M. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin. Oncol. 1999, 26(5 suppl 17):14-18.
7. Petrylak D.P., Tangen C.M., Hussain M.H., Lara P.N., Jones J.A., Taplin M.E., Burch P.A., Berry D., Moinpour C., Kohli M., Benson M.C., Small E.J., Raghavan D., Crawford E.D. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 2004, 351(15):1513-1520.
8. Vaishampayan U., Hussain M. Update in systemic therapy of prostate cancer: improvement in quality and duration of life. Expert Rev. Anticancer Ther. 2008, 8(2):269-281.
9. Assikis V.J., Simons J.W. Novel therapeutic strategies for androgen-independent prostate cancer: an update. Semin. Oncol. 2004, 31:26-32.
10. Retter A.S., Gulley J.L., Dahut W.L. Novel therapeutic strategies in prostate cancer. Cancer Biol. Ther. 2004, 3(4):371-376.
11. Kopecek J. Smart and genetically engineered biomaterials and drug delivery systems. Eur. J. Pharm. Sci. 2003, 20(1):1-16.
12. Duncan R. Polymer conjugates for tumour targeting and intracytoplasmic delivery. The EPR effect as a common gateway?. Pharm. Sci. Technol. Today 1999, 2(11):441-449.
13. Shen H., Hu X., Yang F., Bei J., Wang S. An injectable scaffold: rhBMP-2-loaded poly(lactide-co-glycolide)/hydroxyapatite composite microspheres. Acta Biomater. 2010, 6(2):455-465.
14. Huang J., Lin Y.W., Fu X.W., Best S.M., Brooks R.A., Rushton N., Bonfield W. Development of nano-sized hydroxyapatite reinforced composites for tissue engineering scaffolds. J. Mater. Sci. Mater. Med. 2007, 18(11):2151-2157.
15. Hideki A., Masataka O. Effects of Adracin-adsorbing HAP-sol on Ca-9 cell growth. Reports Institute Med. Dental Eng. 1993, 27:39-44.
16. Stein C.A. Mechanisms of action of taxanes in prostate cancer. Semin. Oncol. 1999, 26(5 suppl 17):3-7.
17. Wolter K.G., Hsu Y.T., Smith C.L., Nechushtan A., Xi X.G., Youle R.J. Movement of Bax from the cytosol to mitochondria during apoptosis. J. Cell Biol. 1997, 139(5):1281-1292.
18. Liu Z.S., Tang S.L., Ai Z.L. Effects of hydroxyapatite nanoparticles on proliferation and apoptosis of human hepatoma BEL-7402 cells. World J. Gastroenterol. 2003, 9(9):1968-1971.
19. Li G., Huang J., Li Y., Zhang R., Deng B., Zhang J., Aoki H. In vitro study on influence of a discrete nano-hydroxyapatite on leukemia P388 cell behavior. Biomed. Mater. Eng. 2007, 17(5):321-327.
20. Wang Y.J., Lai C., Wei K., Chen X.F., Ding Y., Wang Z.L. Investigations on their formation mechanism of hydroxyapatite synthesized by solvothermal method. Nanotechnology 2006, 17:4405-4412.
21. Wei K., Wang Y.J., Lai C., Ning C.Y., Wu D.X., Zhao N.R., Chen X.F., Ye J.D. Synthesis and characterization of hydroxyapatite nanobelts and nanoparticles. Mater. Lett. 2005, 59:220-225.
22. Lee M.K., Lim S.J., Kim C.K. Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles. Biomaterials 2007, 28(12):2137-2146.
23. Zhang X.D., Zhang X.Y., Gray C.P., Nguyen T., Hersey P. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by smac/DIABLO release from mitochondria. Cancer Res. 2001, 61(19):7339-7348.
24. Zhang X.D., Wu J.J., Gillespie S., Borrow J., Hersey P. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin. Clin. Cancer Res. 2006, 12(4):1355-1364.
25. van Vlerken L.E., Vyas T.K., Amiji M.M. Poly(ethylene glycol)-modified nanocarriers for tumor-targeted and intracellular delivery. Pharm. Res. 2007, 24(8):1405-1414.
26. Links M., Brown R. Clinical relevance of the molecular mechanisms of resistance to anti-cancer drugs. Expert Rev. Mol. Med. 1999, 1999:1-21.
27. Wen X., Li X., Liao B., Liu Y., Wu J., Yuan X., Ouyang B., Sun Q., Gao X. Knockdown of p21-activated kinase 6 inhibits prostate cancer growth and enhances chemosensitivity to docetaxel. Urology 2009, 73(6):1407-1411.
28. Panyam J., Labhasetwar V. Sustained cytoplasmic delivery of drugs with intracellular receptors using biodegradable nanoparticles. Mol. Pharm. 2004, 1(1):77-84.
29. Cossarizza A., Baccarani-Contri M., Kalashnikova G., Franceschi C. A new method for the cytofluorimetric analysis of mitochondrial membrane potential using the J-aggregate forming lipophilic cation 5, 5', 6, 6'-tetrachloro-1, 1', 3, 3'-tetraethylbenzimidazolcarbocyanine iodide (JC-1). Biochem. Biophys. Res. Commun. 1993, 197(1):40-45.
30. Muenchen H.J., Poncza P.J., Pienta K.J. Different docetaxel-induced apoptotic pathways are present in prostate cancer cell lines LNCaP and PC-3. Urology 2001, 57(2):366-370.
31. Chan J.M., Zhang L., Yuet K.P., Liao G., Rhee J.W., Langer R., Farokhzad O.C. PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery. Biomaterials 2009, 30(8):1627-1634.
32. Xu Q., Tanaka Y., Czernuszka J.T. Encapsulation and release of a hydrophobic drug from hydroxyapatite coated liposomes. Biomaterials 2007, 28(16):2687-2694.
33. Romberg B., Hennink W.E., Storm G. Sheddable coatings for long-circulating nanoparticles. Pharm. Res. 2008, 25(1):55-71.
34. Hobbs S.K., Monsky W.L., Yuan F., Roberts W.G., Griffith L., Torchilin V.P., Jain R.K. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl. Acad. Sci. U. S. A. 1998, 95(8):4607-4612.
35. Yuan F., Dellian M., Fukumura D., Leunig M., Berk D.A., Torchilin V.P., Jain R.K. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 1995, 55(17):3752-3756.
36. Charrois G.J., Allen T.M. Rate of biodistribution of STEALTH liposomes to tumor and skin: influence of liposome diameter and implications for toxicity and therapeutic activity. Biochim. Biophys. Acta 2003, 1609(1):102-108.
37. Fabbri F., Brigliadori G., Carloni S., Ulivi P., Tesei A., Silvestrini R., Amadori D., Zoli W. Docetaxel-ST1481 sequence exerts a potent cytotoxic activity on hormone-resistant prostate cancer cells by reducing drug resistance-related gene expression. Prostate 2010, 70(2):219-227.
38. Jiang W., Kim B.Y., Rutka J.T., Chan W.C. Nanoparticle-mediated cellular response is size-dependent. Nat. Nanotechnol. 2008, 3(3):145-150.
39. Huang X., Teng X., Chen D., Tang F., He J. The effect of the shape of mesoporous silica nanoparticles on cellular uptake and cell function. Biomaterials 2010, 31(3):438-448.
40. Lassus P., Opitz-Araya X., Lazebnik Y. Requirement for caspase-2 in stress-induced apoptosis before mitochondrial permeabilization. Science 2002, 297(5585):1352-1354.
41. Mhaidat N.M., Wang Y., Kiejda K.A., Zhang X.D., Hersey P. Docetaxel-induced apoptosis in melanoma cells is dependent on activation of caspase-2. Mol. Cancer Ther. 2007, 6(2):752-761.
42. Guo Y., Srinivasula S.M., Druilhe A., Fernandes-Alnemri T., Alnemri E.S. Caspase-2 induces apoptosis by releasing proapoptotic proteins from mitochondria. J. Biol. Chem. 2002, 277(16):13430-13437.